PO.ET06.01 · 实验与分子治疗
铁死亡在卵巢癌中需要caspase-5依赖的GSDME切割
Ferroptosis necessitates caspase 5 dependent GSDME cleavage in ovarian cancer
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
铁死亡是一种由细胞内铁催化、由致死性脂质活性氧(ROS)诱导的膜损伤驱动的程序性细胞死亡(PCD)形式,作为一种新发现的PCD通路,其执行过程在机制上尚未被阐明。本研究旨在阐明卵巢癌中铁死亡的分子执行级联,并确定其是否使用与其他PCD机制共享的共同效应蛋白。将间充质样卵巢癌细胞(OCC1、OVCAR8、ES2)暴露于Erastin和ML162并联合通路特异性抑制剂,结果表明只有焦亡抑制剂YVAD降低了铁死亡诱导的死亡,支持焦亡执行分子的参与。乳酸脱氢酶(LDH)释放和IL-1beta分泌表明铁死亡激活了一种成孔执行过程,而YVAD和gasdermin抑制剂双硫仑均可保护细胞免受膜损伤。铁死亡细胞表现出Gasdermin E(GSDME)的切割,而Gasdermin D未被加工。敲低GSDME可保护卵巢癌细胞免于铁死亡,证实了其在执行阶段的关键作用。我们的研究进一步表明,铁死亡不遵循经典的炎症小体通路,表现为caspase-1保持无活性,且NLRP3抑制(MCC950)和ASC敲低均不影响铁死亡敏感性。非经典焦亡PCD执行分子中,特别是caspase-5在铁死亡过程中被激活,而caspase-4未被激活。此外,siRNA敲低和CRISPR-Cas9敲除caspase-5显著抑制了铁死亡。无细胞生化实验表明,活性caspase-5直接切割全长GSDME,证实了caspase-5激活与成孔之间的相互作用。氧化脂质组学分析发现铁死亡细胞中氧化型磷脂酰乙醇胺(PE)种类的积累,提示其可能是caspase-5/GSDME激活的上游触发因素。我们的数据定义了一条由caspase-5激活和GSDME切割介导的新型铁死亡执行通路,揭示了一种在卵巢癌中具有潜在治疗意义的机制。
查看英文原文 English abstract
Ferroptosis, an intracellular iron-catalyzed form of programmed cell death (PCD) driven by lethal lipid reactive oxygen species (ROS)-induced membrane damage, is mechanistically uncharacterized in its execution process as a newly discovered PCD pathway. This study aimed to elucidate the molecular execution cascade of ferroptosis in ovarian cancer and to determine whether it uses common effector proteins shared with other PCD mechanisms. Mesenchymal-like ovarian cancer cells (OCC1, OVCAR8, ES2) were exposed to Erastin and ML162 with pathway-specific inhibitors, providing evidence that only the pyroptosis inhibitor YVAD reduced ferroptosis-induced death, supporting the association of pyroptotic executors. Lactate dehydrogenase (LDH) release and IL-1beta secretion indicated that ferroptosis activates a pore-forming execution process, while both YVAD and gasdermin inhibitor disulfiram protected membrane damage. Ferroptotic cells exhibited cleavage of Gasdermin E (GSDME), whereas Gasdermin D was not processed. GSDME knockdown protected ovarian cancer cells from ferroptotic death, confirming its essential role in the execution phase. Our study further illustrated that ferroptosis does not follow the canonical inflammasome pathway by showing that caspase-1 remained inactive, and both NLRP3 inhibition (MCC950) and ASC knockdown did not affect ferroptotic sensitivity. Noncanonical pyroptotic PCD executors, specifically caspase-5 was activated during ferroptosis, but not caspase-4. Additionally, the siRNA Knockdown and CRISPR-Cas9 knockout of caspase-5 significantly suppressed ferroptotic death. The cell-free biochemical assay demonstrated that active caspase-5 directly cleaves full-length GSDME, confirming the interaction between caspase-5 activation and pore formation. Oxidized lipidomic profiling identified the accumulation of oxidized phosphatidylethanolamine (PE) species in ferroptotic cells, suggesting a potential upstream trigger for caspase-5/GSDME activation. Our data define a novel ferroptosis execution pathway mediated by caspase-5 activation and GSDME cleavage, revealing a mechanism with potential therapeutic relevance in ovarian cancer.
利益披露 Disclosure
M. Akter,
University of Florida Employment.
L. Sun,
University of Florida Employment.
S. Huang,
University of Florida Employment.